Does Kisqali Cause Heart Rhythm Changes?
Yes, Kisqali (ribociclib) can cause heart rhythm changes, primarily QT interval prolongation, which raises the risk of serious arrhythmias like torsades de pointes.[1][2] This effect stems from the drug's inhibition of cardiac potassium channels, slowing repolarization and extending the QT interval on ECGs.[3]
How Common Is QT Prolongation with Kisqali?
In clinical trials, QT prolongation occurred in 14-17% of patients at the 600 mg dose, with grade 3 or higher cases in about 1-3%.[1][4] Risk increases with higher doses, and post-marketing reports note rare ventricular arrhythmias and sudden cardiac death.[2]
What Increases the Risk?
Factors amplifying QT prolongation include:
- Concurrent use of other QT-prolonging drugs (e.g., certain antibiotics, antifungals, or antiemetics).
- Electrolyte imbalances like low potassium or magnesium.
- Pre-existing heart conditions or baseline QT prolongation.
- Liver impairment or older age.[1][3]
Guidelines recommend ECG monitoring before starting, on day 14 of cycle 1, and before cycle 2, with dose adjustments if QTc exceeds 481 ms.[1]
What Do Patients Report?
Real-world data from FDA adverse event reports show heart rhythm issues like palpitations, tachycardia, and bradycardia linked to Kisqali, though causality isn't always confirmed.[5] Some patients describe fluttering or irregular beats starting weeks into treatment.
How Does Kisqali Compare to Similar Drugs?
Kisqali's QT risk is higher than tamoxifen but similar to other CDK4/6 inhibitors:
| Drug | QT Prolongation Incidence (Grade 3+) |
|------|-------------------------------------|
| Kisqali | 1-3% [1] |
| Verzenio (abemaciclib) | <1% [6] |
| Ibrance (palbociclib) | Rare (<1%) [7] |
Verzenio and Ibrance carry less emphasis on routine ECG monitoring.[6][7]
Monitoring and Management Tips
Avoid starting Kisqali if baseline QTc >450 ms (men) or >470 ms (women). Correct electrolytes before dosing, and hold treatment if QTc >500 ms.[1] No specific antidote exists; management focuses on discontinuation and supportive care.
[1]: Kisqali Prescribing Information (Novartis)
[2]: FDA Label for Ribociclib
[3]: QT Prolongation Mechanism Review, J Clin Oncol (2018)
[4]: MONALEESA-7 Trial Data, N Engl J Med (2019)
[5]: FDA FAERS Database
[6]: Verzenio Prescribing Information (Lilly)
[7]: Ibrance Prescribing Information (Pfizer)